ImportRefusal LogoImportRefusal

Novartis Pharma Ag

⚠️ Moderate Risk

FEI: 3000189692 • Basel Town, Basel Town • SWITZERLAND

FEI

FEI Number

3000189692

📍

Location

Basel Town, Basel Town

🇨🇭
🏢

Address

Klybeckstrasse 141, , Basel Town, Basel Town, Switzerland

Moderate Risk

FDA Import Risk Assessment

49.0
LowModerateHighCritical

This firm has a moderate history of FDA import refusals. Some attention may be warranted.

Statistics

22
Total Refusals
3
Unique Violations
5/19/2020
Latest Refusal
2/22/2005
Earliest Refusal

Score Breakdown

Violation Severity
81.2×40%
Refusal Volume
50.4×30%
Recency
0.0×20%
Frequency
14.4×10%
How is this score calculated?

Proprietary Algorithm

  • 40% Violation Severity — AI-assessed (1-10)
  • 30% Refusal Volume — Logarithmic scale
  • 20% Recency — Decays over 5 years
  • 10% Frequency — Refusals per year

© ImportRefusal.com Original Analysis

Violation Summary

7518×

UNAPPROVED

The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).

1184×

NOT LISTED

It appears the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by section 510(j) or 510(k).

163×

DIRECTIONS

The article is subject to refusal of admission pursuant to section 801(a)(3) in that it is a device whose label appears to not bear adequate directions for use.

Refusal History

DateProductViolationsDivision
5/19/2020
61KDQ99ANTI-CHOLINERGIC, N.E.C.
75UNAPPROVED
Division of Southeast Imports (DSEI)
5/18/2020
62ODA12VALSARTAN (ANTI-HYPERTENSIVE - PART II)
75UNAPPROVED
Division of Northern Border Imports (DNBI)
5/4/2020
62GDY90DICLOFENAC POTASSIUM (ANTI-INFLAMMATORY)
75UNAPPROVED
Division of Southeast Imports (DSEI)
3/26/2019
66NCY07OXCARBAZEPINE (TRANQUILIZER (ANTI-PSYCHOTIC) - PART II)
75UNAPPROVED
Division of Southeast Imports (DSEI)
12/11/2018
62GCO18DICLOFENAC SODIUM (ANTI-INFLAMMATORY)
75UNAPPROVED
Division of Southeast Imports (DSEI)
9/11/2018
66YDB99EXHIBITS - OTHER DRUG RELATED ITEMS N.E.C.
118NOT LISTED
75UNAPPROVED
Division of Southeast Imports (DSEI)
5/4/2018
61PCA99ANTI-DIABETIC N.E.C.
75UNAPPROVED
Division of Southeast Imports (DSEI)
1/12/2017
66VIY99MISCELLANEOUS PATENT MEDICINES, ETC.
75UNAPPROVED
Philadelphia District Office (PHI-DO)
1/12/2017
66VIY99MISCELLANEOUS PATENT MEDICINES, ETC.
75UNAPPROVED
Philadelphia District Office (PHI-DO)
9/6/2016
66VIY99MISCELLANEOUS PATENT MEDICINES, ETC.
75UNAPPROVED
Philadelphia District Office (PHI-DO)
7/13/2016
61NCB11CLOMIPRAMINE HCL (ANTI-DEPRESSANT)
118NOT LISTED
Florida District Office (FLA-DO)
5/27/2016
66YIH99EXHIBITS - OTHER DRUG RELATED ITEMS N.E.C.
75UNAPPROVED
Florida District Office (FLA-DO)
8/13/2015
66VCY99MISCELLANEOUS PATENT MEDICINES, ETC.
75UNAPPROVED
Division of Northern Border Imports (DNBI)
1/7/2012
60CCQ53XYLOMETAZOLINE HCL (ADRENERGIC)
75UNAPPROVED
New Orleans District Office (NOL-DO)
12/5/2011
64TDE09IMATINIB MESYLATE (IMMUNOSUPPRESSIVE)
75UNAPPROVED
New Orleans District Office (NOL-DO)
5/20/2009
61WBA52TERBINAFINE HYDROCHLORIDE (ANTI-FUNGAL) (NOT ANTIBIOTIC)
75UNAPPROVED
New Orleans District Office (NOL-DO)
5/20/2009
61WBO52TERBINAFINE HYDROCHLORIDE (ANTI-FUNGAL) (NOT ANTIBIOTIC)
75UNAPPROVED
New Orleans District Office (NOL-DO)
11/20/2008
68YCH10SMALL ANIMAL ANIMAL DRUGS N.E.C.
16DIRECTIONS
New York District Office (NYK-DO)
9/1/2006
65UCP02TRIBENOSIDE (SCLEROSING AGENT)
75UNAPPROVED
New Orleans District Office (NOL-DO)
4/20/2005
66VIR99MISCELLANEOUS PATENT MEDICINES, ETC.
75UNAPPROVED
New York District Office (NYK-DO)
3/18/2005
61HIR99ANTI-BACTERIAL, N.E.C.
118NOT LISTED
16DIRECTIONS
New York District Office (NYK-DO)
2/22/2005
61HIR99ANTI-BACTERIAL, N.E.C.
118NOT LISTED
16DIRECTIONS
New York District Office (NYK-DO)

Frequently Asked Questions

What is Novartis Pharma Ag's FDA import refusal history?

Novartis Pharma Ag (FEI: 3000189692) has 22 FDA import refusal record(s) in our database, spanning from 2/22/2005 to 5/19/2020.

What is an FEI number?

FEI stands for Firm Establishment Identifier. It's a unique number assigned by the FDA to identify establishments that manufacture, process, pack, or hold food, drugs, medical devices, or other FDA-regulated products. Novartis Pharma Ag's FEI number is 3000189692.

What types of violations has Novartis Pharma Ag received?

Novartis Pharma Ag has been cited for 3 different violation type(s). Common FDA violations include adulteration (unsafe or unsanitary products), misbranding (incorrect or misleading labels), and regulatory non-compliance.

Where does this information about Novartis Pharma Ag come from?

All FDA import refusal data for Novartis Pharma Ag is sourced from the official FDA Data Dashboard (datadashboard.fda.gov), a public government database maintained by the U.S. Food and Drug Administration.

Data sourced from the FDA Data Dashboard, a public database maintained by the U.S. Food and Drug Administration.